{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-056966","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.237672+00:00","generated_at":"2026-06-05T05:11:57.366151+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nektar Therapeutics raises $30M via pre-funded warrant to TCG Crossover Fund","bullets":["Issued pre-funded warrant to purchase 25M shares of common stock at $1.20 per share, total $30M.","Exercise price of warrant is $0.0001 per share; purchaser cannot exceed 9.99% beneficial ownership without notice.","Closing expected on or before March 6, 2024; exempt from registration under Section 4(a)(2) and Rule 506(b).","Company to file resale registration statement for warrant shares within 90 days after closing.","Use of proceeds not specified; proceeds before expenses are $30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-056966","json":"https://secwatch.observer/filing/0001193125-24-056966.json","markdown":"https://secwatch.observer/filing/0001193125-24-056966.md","text":"https://secwatch.observer/filing/0001193125-24-056966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/0001193125-24-056966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/d762406d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:11:57.366151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1648fa80ea768d46d5b9dc126d0e9da676144854","claim":"NEKTAR THERAPEUTICS entered into Purchase Agreement with TCG Crossover Fund II, L.P. valued at $30.0 million (effective 2024-03-04).","evidence_excerpt":"On March 4, 2024, Nektar Therapeutics (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with TCG Crossover Fund II, L.P. (the “Purchaser”), for the private placement (the “Private Placement”) of a pre-funded warrant (the “Pre-Funded Warrant”) to purchase 25,000,000 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (the “Warrant Shares” and together with the Pre-Funded Warrant, the “Securities”), at a total purchase price of $30.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/0001193125-24-056966-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"TCG Crossover Fund II, L.P."},{"label":"Value","value":"$30.0 million"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}